On April 29, 2025, Abeona Therapeutics Inc. announced that the U.S. FDA approved ZEVASKYN™, the first cell-based gene therapy for patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB). This marks a significant advancement in treatment for this condition.